The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients ...

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, ...

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Panelists discuss how combination therapies targeting different aspects of spinal muscular atrophy (SMA), such as myostatin ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Panelists discuss how insurance challenges impact spinal muscular atrophy (SMA) care, with prior authorizations becoming more ...

Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...